# Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin

> **NCT06886464** · PHASE2 · RECRUITING · sponsor: **Matthew James** · enrollment: 698 (estimated)

## Conditions studied

- Acute Kidney Injury

## Interventions

- **DRUG:** Cilastatin Sodium
- **DRUG:** Placebo-Saline

## Key facts

- **NCT ID:** NCT06886464
- **Lead sponsor:** Matthew James
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-16
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12
- **Target enrollment:** 698 (ESTIMATED)
- **Last updated:** 2025-11-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06886464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06886464, "Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06886464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*